Payment overview · 2025
General Payments
$471.47
21 reported records · 9 companies
Healthcare provider profile · identity verified
Farid Saadat, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKE ELSINORE, CA · NPI 1891767935
Verified facts
What the public records show
CMS Open Payments records show Farid Saadat, MD received $471.47 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 55.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $259.69 | 55.1% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.47 | 12.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.32 | 8.8% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $26.43 | 5.6% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $22.91 | 4.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.95 | 4.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.16 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.84 | 2.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.70 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $471.47 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $192.47 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $146.85 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $114.05 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $56.47 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $41.32 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.95 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 79 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 107 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 109 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
107 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
109 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1081 | 324 |
| Levothyroxine Sodium | Levothyroxine Sodium | 635 | 165 |
| Metformin Hcl | Metformin Hcl | 527 | 144 |
| Lisinopril | Lisinopril | 501 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 417 | 128 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 362 | 59 |
| Losartan Potassium | Losartan Potassium | 351 | 103 |
| Folic Acid | Folic Acid | 305 | 102 |
| Omeprazole | Omeprazole | 283 | 86 |
| Trazodone Hcl | Trazodone Hcl | 261 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 246 | 77 |
| Fluticasone Propionate | Fluticasone Propionate | 239 | 73 |
| Tamsulosin Hcl | Tamsulosin Hcl | 230 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 68 |
| Gabapentin | Gabapentin | 202 | 54 |
| Furosemide | Furosemide | 186 | 56 |
| Famotidine | Famotidine | 161 | 45 |
| Eliquis | Apixaban | 160 | 39 |
| Simvastatin | Simvastatin | 155 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 154 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 44 |
| Meloxicam | Meloxicam | 135 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 29 |
| Atenolol | Atenolol | 111 | 27 |
| Finasteride | Finasteride | 109 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 109 | 34 |
| Jardiance | Empagliflozin | 107 | 31 |
| Tramadol Hcl | Tramadol Hcl | 104 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 104 | 50 |
| Glimepiride | Glimepiride | 100 | 34 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 99 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 13 |
| Allopurinol | Allopurinol | 93 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 35 |
| Ibuprofen | Ibuprofen | 91 | 20 |
| Lovastatin | Lovastatin | 88 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 85 | 11 |
| Clonazepam | Clonazepam | 84 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 81 | 32 |
| Farxiga | Dapagliflozin Propanediol | 79 | 23 |
| Carvedilol | Carvedilol | 78 | 26 |
| Ozempic | Semaglutide | 76 | 12 |
| Potassium Chloride | Potassium Chloride | 73 | 25 |
| Azithromycin | Azithromycin | 68 | 57 |
| Glipizide | Glipizide | 68 | 27 |
| Benazepril Hcl | Benazepril Hcl | 67 | 17 |
| Alendronate Sodium | Alendronate Sodium | 66 | 16 |
| Alprazolam | Alprazolam | 62 | 11 |
| Chlorthalidone | Chlorthalidone | 62 | 20 |
| Ketoconazole | Ketoconazole | 60 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 56 | 26 |
| Sertraline Hcl | Sertraline Hcl | 56 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 40 |
| Baclofen | Baclofen | 50 | suppressed |
| Lorazepam | Lorazepam | 49 | suppressed |
| Myrbetriq | Mirabegron | 48 | 16 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Memantine Hcl | Memantine Hcl | 46 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 45 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | suppressed |
| Temazepam | Temazepam | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 14 |
| Donepezil Hcl | Donepezil Hcl | 41 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 36 |
| Nitroglycerin | Nitroglycerin | 40 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 11 |
| Alcohol Pads | Alcohol Antiseptic Pads | 38 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 38 | 11 |
| Levemir Flexpen | Insulin Detemir | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | 15 |
| Topiramate | Topiramate | 33 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Prednisone | Prednisone | 31 | 21 |
| Meclizine Hcl | Meclizine Hcl | 29 | 14 |
| Rybelsus | Semaglutide | 28 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 28 | 12 |
| Acyclovir | Acyclovir | 27 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Ezetimibe | Ezetimibe | 25 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 23 |
| Methocarbamol | Methocarbamol | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| V-Go 30 | Sub-Q Insulin Device, 30 Unit | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 20 |
| Insulin Lispro | Insulin Lispro | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| V-Go 20 | Sub-Q Insulin Device, 20 Unit | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Apidra | Insulin Glulisine | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Calcipotriene | Calcipotriene | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $471.47 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, JOURNAVX, Ozempic, Rybelsus, TRELEGY ELLIPTA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error